Bruker (NASDAQ:BRKR) Releases FY 2025 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 1.850-1.90 for the period, compared to the consensus earnings per share estimate of 1.960. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.4 billion.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BRKR. Stifel Nicolaus set a $40.00 price target on Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Barclays decreased their price target on Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Citigroup reduced their target price on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, August 4th. Finally, Wells Fargo & Company reduced their target price on Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $51.00.

Bruker Stock Performance

BRKR stock opened at $38.94 on Monday. Bruker has a twelve month low of $28.53 and a twelve month high of $64.64. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The business’s fifty day simple moving average is $34.44 and its two-hundred day simple moving average is $36.97. The firm has a market cap of $5.91 billion, a price-to-earnings ratio of 74.89, a PEG ratio of 5.31 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the prior year, the company earned $0.60 EPS. The business’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Analysts predict that Bruker will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s dividend payout ratio is presently 38.46%.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares of the company’s stock, valued at approximately $581,016. This represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in BRKR. Royal Bank of Canada boosted its position in Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after purchasing an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Bruker during the first quarter valued at about $262,000. Goldman Sachs Group Inc. boosted its holdings in Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after acquiring an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth boosted its holdings in Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after acquiring an additional 6,008 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.